Donepezil in the treatment of patients with Alzheimer's disease.
Alzheimer's disease (AD) is the most common cause of dementia and is characterized by an insidious onset and slow deterioration in cognition, activities of daily living (ADL), mood stability and social functioning. The cholinesterase inhibitors (ChEIs), developed based on the cholinergic hypothesis, are currently considered to be the best established treatment for AD, although the significant advances in the symptomatic pharmacotherapy of AD may be followed by disease-modification treatments. Donepezil is a mixed competitive and noncompetitive acetylcholinesterase inhibitor that shows a relative selectivity for acetylcholinesterase inhibitor compared with butyrylcholinesterase. In many clinical trials of donepezil, beneficial effects on standard measures of cognitive function, ADL and behavior have been shown in patients with mild, moderate or severe AD. Although the pharmacological and phamacokinetic profiles of the currently available ChEIs have notable differences that may affect efficacy, the clinical significance of these differences remains hypothetical in the absence of large, randomized trials that compare the ChEIs with each other.
Tsuno
Norifumi
N
Department of Psychiatry, Tokyo Jikei University School of Medicine, Tokyo, Japan. tsuno@jikei.ac.jps
D000544:Alzheimer Disease / Q000188:drug therapy*; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil